Seattle Children’s Research Institute and Juno Therapeutics are planning to speed up the process of making cutting-edge cancer treatments available to children and adults with brain tumors.
The treatments, called T-cell immunotherapies, use a patient’s immune system components to attack the cancer. Seattle-based Juno Therapeutics (Nasdaq: JUNO) is a pioneer in this field, as is the director of the collaboration for Seattle Children’s, Dr. Mike Jensen.
This latest collaboration between the…
Seattle Children’s Research Institute and Juno Therapeutics are planning to speed up the process of making cutting-edge cancer treatments available to children and adults with brain tumors.
The treatments, called T-cell immunotherapies, use a patient’s immune system components to attack the cancer. Seattle-based Juno Therapeutics (Nasdaq: JUNO) is a pioneer in this field, as is the director of the collaboration for Seattle Children’s, Dr. Mike Jensen.
This latest collaboration between the…
